Dr. Schecter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
920 US-202 S
Raritan, NJ 08869Phone+1 908-927-3159- Is this information wrong?
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2007
Brown UniversityInternship, Internal Medicine, 2004 - 2005
The Warren Alpert Medical School of Brown UniversityClass of 2004
Certifications & Licensure
NY State Medical License 2006 - 2025
Clinical Trials
- Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- 11 citationsPhase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/...Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, Weijun Fu, Jianda Hu, Lijuan Chen, Yiwen Zhang, Dan Yao, Diana Chen, Jordan M Schecter, Fan Yang, Xiaochen Tian, Huabin Sun, ...> ;Journal of Clinical Oncology. 2023 Feb 20
- 139 citationsCiltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C Munshi...> ;Journal of Clinical Oncology. 2023 Feb 20
- 7 citationsAdjusted comparison of outcomes between patients from CARTITUDE-1multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and ant...Maria-Victoria Mateos, Katja Weisel, Thomas Martin, Jesús G Berdeja, Andrzej Jakubowiak, A Keith Stewart, Sundar Jagannath, Yi Lin, Joris Diels, Francesca Ghilotti, Pu...> ;Haematologica. 2023 Aug 1
- Join now to see all
Abstracts/Posters
- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
FDA Panel Approves 2 New CAR-T TherapiesMarch 16th, 2024- Treatment with CARVYKTI®▼ (Ciltacabtagene Autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple MyelomaDecember 16th, 2023
- Treatment with CARVYKTI® (Ciltacabtagene Autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple MyelomaDecember 16th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
